Novelion Therapeutics Inc.Company Review & Valuation

NVLN
Nasdaq

About Novelion Therapeutics Inc.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholShow moreesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Show less

Industry
Biotechnology
HQ Location
Vancouver, Canada

Stock Price

Price data not available for Novelion Therapeutics Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

United Therapeutics
ACADIA Pharmaceuticals
Amgen
RedHill Biopharma

back to top